The content on this site is intended for healthcare professionals only
Dr Bijal Shah speaks to ecancer about the phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukaemia.
Initially, he explains the rationale of this study.
Dr Shah then discusses the methodology and key findings of this study.
He mentions that as of 9/2020, 55 of 71 enrolled patients received KTE-X19, with a median follow-up of 16.4 months. Adverse events and ineligibility were the most common reasons enrolled patients did not receive KTE-X19 infusion.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Multiple myeloma in a resource constrained setting
Ide-cell enhances health-related quality of life for refractory multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
